we have a drug, even many drugs, good for so many indications, to become a giant pharma, we are about to get billions in revenues.

$HTGM A penny with cash and increasing revenue.

Revenue will pour in.

As investors digest the revenue potential, either via approval for RETT, or partnership for AD and PD, the stock price will rise accordingly.

$PDD closed 12.62% higher on Monday after the company reported a 65% year-over-year growth in its third-quarter revenue.

$HKD: The Revenue has been growing by 138.30% on average over the past 5 years.

$HKD: The Revenue has been growing by 138.30% on average over the past 5 years.

$HKD: The Revenue has been growing by 138.30% on average over the past 5 years.

$HKD: The Revenue has been growing by 138.30% on average over the past 5 years.

$HKD shows a strong growth in Revenue.

$HKD: The Revenue has been growing by 138.30% on average over the past 5 years.

So many avenues for revenue with HKD.

$HKD: The Revenue has been growing by 138.30% on average over the past 5 years.

$HKD it's pretty simple, no debt, crazy amount of cash, huge increase first six months revenue and way undervalued.

No debt, ridiculous balance sheet and 98 percent profit margins + 130 Percent Revenue Growth.

Two other drugs, each growing revenue steadily.

That said, I fully expect continuing script and revenue growth, upcoming cashflow breakeven and some nice juicy licensing deals to resolve that in the months ahead.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

There is so much good news here, growing revenue, a stable base, conservative management, and connections to big pharma.